Imatinib (STI571) 是一种口服生物可用的酪氨酸激酶抑制剂，可选择性抑制 BCR/ABL，v-Abl，PDGFR，c-kit 激酶活性。Imatinib (STI571) 靠近 ATP 结合位点结合，将其锁定在封闭或自我抑制的构象中，因此半竞争性抑制蛋白质的酶活性。Imatinib 还抑制 SARS-CoV 和 MERS-CoV。
| CAS No. | 152459-95-5 |
| 生物活性 | Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV. |
| 分子式 | C29H31N7O |
| 分子量 | 493.60 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存条件 | Powder -20°C 3 years |
| 溶解性数据 | DMSO : 12.5 mg/mL (25.32 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble) |
| 体内研究 | In the phosphorothioate antisense oligodeoxynucleotides (PS-ASODN) group, tumor growth is inhibited by 59.437%, which is markedly higher than in the Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and group (11.071%) and liposome negative control group (2.759%). Telomerase activity is significantly lower (P<0.01) in the PS-ASODN group (0.689±0.158) compare with the Imatinib group (1.838±0.241), liposome negative control group (2.013±0.273), and saline group (2.004±0.163). Imatinib (25 mg/kg/day, p.o.) suppresses the growth of endometriotic tissue and reduces the number of ovarian follicles in a rat model. Imatinib effectively treats experimental endometriosis by its inhibitor effects on angiogenesis and cell proliferation. |
| 体外研究 | Imatinib (STI571) inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. The concentration that produces 50% inhibition for these effects is approximately 100 nM. Imatinib (STI571) is very effective (in vitro IC50 of 25 nM) against the chronic myeloid leukemia-causing kinase Bcr-Abl. Imatinib also efficiently inhibits Kit (in vitro IC50, 410 nM) and PDGFR (in vitro IC50, 380 nM). Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and inhibits Bcr/Abl, v-Abl, Tel/Abl, the native PDGFβ receptor, and c-Kit, but it does not inhibit Src family kinases, c-Fms, Flt3, the EGFR or multiple other tyrosine kinases. Imatinib inhibits tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case, but it has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2. The IC50s of Imatinib(STI571) is a multi-target inhibitor of v-Abl, c-Kit and on BON-1 and H727 cells after exposure for 48 h are 32.4 and 32.8 μM, respectively. |
| 文献 | •Nat Biomed Eng. 2018 Aug;2(8):578-588. •Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. •Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. •EMBO Mol Med. 2021 Mar 4;e13144. •Theranostics. 2021 Jan 1;11(6):2691-2705. •Genes Dev. 2021 Oct 1;35(19-20):1356-1367. •Clin Cancer Res. 2020 Aug 15;26(16):4349-4359. •Cancer Lett. 2019 Apr 10;447:105-114. •Sci Signal. 2019 Jul 16;12(590). pii: eaav7259. •Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4. •J Med Chem. 2021 Feb 23. •J Med Chem. 2019 Jul 11;62(13):6083-6101. •J Med Chem. 2019 May 23;62(10):5006-5024. •J Med Chem. 2016 Sep 22;59(18):8456-72. •Clin Chem. 2019 Dec;65(12):1522-1531. •Cell Biosci. 2020 Feb 12;10:16. •Sensor Actuat B-Chem. 2021, 128991. •Ther Adv Med Oncol. 2019 May 17;11:1758835919849757. •Clin Sci. 2021 Jul 20;CS20210571. •Stem Cell Reports. 2017 Dec 12;9(6):1948-1960. •Viruses. 2021 May 31;13(6):1035. •Cancer Biol Ther. 2019;20(6):877-885. •Cancer Med. 2019 Sep;8(11):5352-5366. •Eur J Pharmacol. 2021 Nov 26;174633. •Eur J Pharmacol. 2021 Jun 1;174217. •Eur J Pharmacol. 2021 Feb 10;173944. •PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. •Mol Cell Biochem. 2020 Jan;463(1-2):67-78 •PLoS One. 2017 Jun 1;12(6):e0178619. •J Bioenerg Biomembr. 2012 Feb;44(1):155-61. •Bioanalysis. 2018 Jul;10(14):1099-1113. •Med Sci Monit. 2017 Aug 6;23:3808-3816. •Biomed Chromatogr. 2019 Dec;33(12):e4674. •Anticancer Drugs. 2014 Jul;25(6):673-82. •Research Square Preprint. 2021 May. •Patent. US20200276189A1. •Oncotarget. 2018 Apr 24;9(31):22158-22183. •Oncotarget. 2017 Nov 15;8(67):111110-111118. •Oncotarget. 2016 Jul 19;7(29):45562-45574. •Harvard Medical School LINCS LIBRARY |
| 纯度及产品资料 | 98% |
邮箱：info@TianyaBio.com
电话：020-3107 8154
地址：广州市番禺区兴业大道东路1078号2-50
微信公众号
微信客服
